Results 31 to 40 of about 292,142 (337)

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada

Drug and Alcohol Dependence Reports, 2023
Background: Among people who inject drugs, frequent injecting and experiencing withdrawal are associated with facilitating others’ first injections. As these factors may reflect an underlying substance use disorder, we investigated whether first-line ...
Zachary Bouck, Andrea C. Tricco, Laura C. Rosella, Hailey R. Banack, Matthew P. Fox, Robert W. Platt, M-J Milloy, Kora DeBeck, Kanna Hayashi, Dan Werb   +9 more
doaj   +1 more source

Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service

Drug and Alcohol Dependence Reports, 2022
Highlights • Hospital-based opioid agonist treatment (OAT) differed by sex, race, and housing status.• Hospital-based OAT was associated with linkage to community-based treatment.• Hospitalization is a reachable moment to initiate OAT.
Courtney D. Nordeck, Christopher Welsh, Robert P. Schwartz, S. Mitchell, Kevin E. O’Grady, J. Gryczynski   +5 more
semanticscholar   +1 more source

Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions

The International journal on drug policy, 2022
Background In March 2020, following a provincial COVID-19 emergency declaration, modifications to opioid agonist treatment (OAT) were introduced in Ontario, Canada to promote treatment access amid the pandemic and ongoing opioid overdose crisis ...
Z. Bouck, A. Scheim, T. Gomes, V. Ling, Alexander Caudarella, D. Werb   +5 more
semanticscholar   +1 more source

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study

BMC Public Health, 2022
Background Incarcerated populations experience an elevated prevalence of opioid use disorder (OUD). Federal correctional institutions in Canada have increasingly treated OUD among correctional populations via opioid agonist treatment (OAT) – an evidence ...
Cayley Russell, Frishta Nafeh, Michelle Pang, S. MacDonald, D. Derkzen, J. Rehm, Benedikt Fischer   +6 more
semanticscholar   +1 more source

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence [PDF]

Cochrane Database of Systematic Reviews, 2011
Maintenance treatments are effective in retaining patients in treatment and suppressing heroin use. Questions remain regarding the efficacy of additional psychosocial services.To evaluate the effectiveness of any psychosocial plus any agonist maintenance treatment versus standard agonist treatment for opiate dependenceWe searched the Cochrane Drugs and
Laura, Amato, Silvia, Minozzi, Marina, Davoli, Simona, Vecchi   +3 more
openaire   +5 more sources

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada

International Journal of Qualitative Studies on Health & Well-Being, 2022
Introduction Correctional populations with opioid use disorder experience increased health risks during community transition periods. Opioid Agonist Treatment (OAT) can reduce these risks, but retention is a key challenge.
Cayley Russell, Michelle Pang, Frishta Nafeh, Shanna Farrell Macdonald, D. Derkzen, J. Rehm, Benedikt Fischer   +6 more
semanticscholar   +1 more source

Selective review and commentary on emerging pharmacotherapies for opioid addiction. [PDF]

, 2011
Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians,
Ling, Walter, Miotto, Karen, Mooney, Larissa, Nielsen, Suzanne, Torrington, Matthew, Zhao, Min   +5 more
core   +2 more sources

Opioid agonist treatment for pharmaceutical opioid dependent people

Cochrane Database of Systematic Reviews, 2014
There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment research has been conducted in people who use heroin.To assess
Nielsen, S, Larance, B, Degenhardt, L, Gowing, L, Kehler, C, Lintzeris, N   +5 more
openaire   +3 more sources

Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

British medical journal, 2020
Objective To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug ...
L. Pearce, J. Min, M. Piske, Haoxuan Zhou, F. Homayra, A. Slaunwhite, M. Irvine, G. McGowan, B. Nosyk   +8 more
semanticscholar   +1 more source

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada

Substance Abuse Treatment, Prevention, and Policy, 2019
Objective The objective was to characterize the relationship between geography, concurrent psychiatric services, all-cause mortality, and acute health care use for individuals enrolled in Opioid Agonist Treatment, in Ontario, Canada. Methods We conducted
Kristen A. Morin, Joseph K. Eibl, Joseph M. Caswell, Graham Gauthier, Brian Rush, Christopher Mushquash, Nancy E. Lightfoot, David C. Marsh   +7 more
doaj   +1 more source